MicroRNA Regulates Drug Tolerance in Subset of Lung Cancers
Written by Jacqueline Mitchell Media Contact: Teresa Herbert, 617-667-7305, firstname.lastname@example.org
APRIL 08, 2019
Quashing the Resistance: Newly identified pathway offers promising targets for preventing tumor relapse
BOSTON – Relapse of disease following conventional treatments remains one of the central problems in cancer management, yet few therapeutic agents targeting drug resistance and tolerance exist. New research conducted at the Cancer Center at Beth Israel Deaconess Medical Center found that a microRNA – a small fragment of non-coding genetic material that regulates gene expression – mediates drug tolerance in lung cancers with a specific mutation. The findings, published today in Nature Metabolism, suggest that the microRNA could serve as a potential target for reversing and preventing drug tolerance in a subset of non-small-cell lung cancers.
“These results were a surprise and represent a total novel finding in the area,” said senior author Frank J. Slack, PhD, Director of the HMS Initiative for RNA Medicine at the Cancer Center at BIDMC. “We have identified a novel pathway required for drug tolerance that is regulated by a microRNA. Targeting this microRNA reduces tolerance, suggesting a potential new approach for treatment of lung cancer.”
Lung cancer is the leading causes of cancer-related deaths among both men and women. As a class, non-small cell lung cancers – which comprise about 85 percent of lung cancer diagnoses – tend to be less aggressive but harder to treat than small cell lung cancers. About one in 10 non-small-cell lung carcinomas carries a mutation to a protein called EGFR on the surface of the cancer’s cells.
Since 2003, several medications that block the activity of the EGFR protein – a class of drugs called tyrosine kinase inhibitors – have received FDA-approval for the treatment of EGFR-positive lung cancers. However, despite patients’ sometimes dramatic initial response to these medications, many patients eventually relapse as their cancer develops resistance to the treatment. By studying drug resistant tumor cells, Slack and colleagues identified the key players driving the development of drug resistance.
“In this study, we discovered that a microRNA known as miR-147b is a critical mediator of resistance among a subpopulation of tumor cells that adopt a tolerance strategy to defend against EGFR-based anticancer treatments,” said Slack, who is also the Shields Warren Mallinckrodt Professor of Medical Research, Departments of Pathology and Medicine, Harvard Medical School. “We are currently testing the idea of targeting this new pathway as a therapy in clinically relevant mouse models of EGFR-mutant lung cancer.”
In addition to Slack, authors include Wen Cai Zhang, He Huang, Min Yuan, Tanvi Saxena, John M. Asara and Daniel B. Costa of BIDMC; Julie M. Wells, Kin-Hoe Chow of Jackson Laboratory for Mammalian Genetics; Mary Ann Melnick and Katerina Politi of Yale University School of Medicine.
This work was supported by NIH-YALE SPORE in Lung Cancer grants P50CA196530 and P50CA196530-03S1; NIH-YALE SPORE in Lung Cancer Career Development Program Award, the BIDMC-JAX collaboration project; the Ludwig Center at Harvard; the National Institutes of Health (grants P30CA034196, 5P01CA120964 and 5P01CA006516); and NRSA grant 5T32HL007893-20. The authors declare no competing interests.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.